Coloplast reports 8% organic growth in Q1 2025 and maintains strong EBIT margin

Coloplast A/S reported an 8% organic growth for Q1 2025, maintaining a reported EBIT margin of 27%. This performance aligns with the company's expectations and shows stability compared to the previous year. The company highlighted that Kerecis, a fish skin technology product, was included in the final Local Coverage Determination Policy for skin substitutes. This recognition is based on strong clinical evidence supporting its effectiveness. Coloplast's adjusted return on invested capital after tax remained steady at 15%, consistent with last year's figures. The company continues to focus on its growth and product development strategies.